Week In Review: Kelun-Biotech In $9.5 Billion ADC Deal With Merck

Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones.

Related Keywords

China ,Australia ,Shanghai ,Singapore ,Suzhou ,Jiangsu ,Kira Pharma ,Sichuan Kelun ,Agency For Science ,Pfizer ,Singapore Experimental Drug Development Centre ,Research Of Singapore ,Greater China ,Shanghai Healthcare Capital ,Shanghai Pharma ,Computational Predictive Biology ,Beijing Biopharma ,Nor Therapeutics ,Borun Investment ,Experimental Drug Development Centre ,China Phase ,Orphan Drug Designation ,China Australia Phase ,